Home
overview
Phage display technologies have become a powerful enabling technology in genomics, drug discovery and development. In particular, phage display has revolutionised the engineering of human antibodies. Display methods also show much promise in the development of therapeutics targeting a whole range of disorders, including cancer, AIDS and autoimmune diseases.

Phage Display Technologies will explore recent developments in this important area. The programme covers areas ranging from improvement of antibody efficiency to enhanced drug discovery applications. Other issues of prime importance to the commercialisation of phage display technologies include strategic alliances, patenting and licensing will also covered.

Why should you attend this event?

This comprehensive conference is organised and produced by SMi: we have identified phage display technologies as an area that is important to executives eager to keep up to date with industry developments in this vital area. As a key industry representative, you are aware of the growing importance of developments that will increase both your efficiency and productivity. SMi conferences are leading-edge business events offering delegates the opportunity to meet senior industry and government figures and seek their advice and opinions. The conference will of course also be an ideal opportunity for you to network with a focused and appropriate audience

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Dr Paul Parren

Dr Paul Parren, Assistant Professor, The Scripps Research Institute

9:10 INTEGRATING DISPLAY TECHNOLOGIES

Dr Hennie Hoogenboom

Dr Hennie Hoogenboom, Senior Vice President, Discovery, Dyax

  • Phage display for antibody lead identification
  • Human Fab display libraries with novel sources of V-gene diversity
  • Proprietary display vectors
  • Combining synthetic and natural antibody diversity
  • Automated selection and screening platforms

    Proprietary display methods for rapid affinity maturation of antibodies

  • Compatible mammalian expression vectors for whole Ig production

    High affinity human antibodies as therapeutics and research reagents

  • 9:40 IMPROVING ANTIBODY EFFICIENCY

    Dr Alessandro Pini

    Dr Alessandro Pini, Postdoctorate Position in Phage Display Facilities, Molecular Biology Department, University of Siena

  • Phage libraries for high affinity antibodies
  • How to construct mimitopes by phage display technology
  • Where to introduce mutations into the antibody fragment genes
  • Antibody engineering based on computer modeling
  • Modeling-directed mutagenesis can bring to high affinity antibodies
  • Future perspectives
  • 10:20 TARGET ISOLATION

    Barbara Morris

    Barbara Morris, Senior Scientist, Product Applications, Novagen

  • Use of lytic phage for display
  • Advantages of C-terminal display
  • Display of larger molecules
  • Examples of target isolation
  • 11:00 Morning Coffee

    11:20 TRANS-PHAGE TECHNOLOGY

    Dr Nils Lonberg

    Dr Nils Lonberg, Senior Vice President, Scientific Director, Medarex

  • Creation and screening of high affinity fully human antibodies
  • Generation of custom libraries
  • Speeding up target to trial times
  • Product development, challenges and opportunities
  • 12:00 DRUG DISCOVERY AND DEVELOPMENT

    Dr Bassil Dahiyat

    Dr Bassil Dahiyat, President & Chief Executive Officer, Xencor

  • cDNA library display for drug discovery
  • Eukaryotic expression of displayed libraries
  • Small molecule interaction profiles with the proteome
  • Target ID and receptor deorphanization
  • Drug development: predictive toxicology
  • 12:40 Networking Lunch

    14:00 DETERMINING DRUG NOVELTY

    Dr Ignace Lasters

    Dr Ignace Lasters, Chief Executive Officer, AlgoNomics

  • Advanced computational tools for prediction of sequence variation
  • Linking proteins with compatible sequence variation
  • Phage display – a method of validating predicted sequence with protein
  • Integration of computational and phage display approaches for optimised experimental design
  • 14:40 TECHNOLOGY DEVELOPMENTS

    Dr David Larocca

    Dr David Larocca, Asociate Director, Research, Selective Genetics

  • Conferred mammalian tropism
  • Receptor-mediated gene delivery by multivalent phage
  • Selection of functional ligands
  • Theratomics: identification of proteins with intrinsic therapeutic value
  • Directed evolution of targeted phage vectors
  • Phage gene therapy
  • 15:20 Afternoon Tea

    15:40 DRUG DISCOVERY APPLICATIONS

    Dr Paul Hamilton

    Dr Paul Hamilton, Director, Research, Karo Bio

  • Phage display libraries – a source of peptides directed to functional sites on protein targets
  • Isolation of potent enzyme inhibitors
  • Intracellular expression of peptides for target validation
  • High throughput screening (HTS) for drug discovery
  • HTS assays for targets of unknown function
  • HTS assays for targets that are difficult to screen by traditional methods

    Application of phage display: assay to screen to hits

  • 16:20 FUNCTIONAL GENOMICS APPLICATIONS

    Dr Sachdev Sidhu

    Dr Sachdev Sidhu, Research Scientist, Genentech

  • Assessing binding energetics at protein-protein interfaces with shotgun scanning mutagenesis
  • Inhibitors of extracellular signalling interactions from naïve peptide libraries
  • Disruption of intracellular signalling complexes for target validation
  • Identification of novel signalling complexes with peptide consensus and database mining
  • Peptidic inhibitors as leads for small molecule design
  • Combining genomics and phage display to study domain families en masse
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Dr Hennie Hoogenboom

    Dr Hennie Hoogenboom, Senior Vice President, Dyax

    9:10 DEVELOPMENT OF mRNA DISPLAY (PROFUSION™ TECHNOLOGY) FOR PROTEOMIC AND THERAPEUTIC APPLICATIONS

    Dr Richard Wagner

    Dr Richard Wagner, Senior Vice President, Research, Phylos

  • Creation of large protein libraries
  • Rapid affinity maturation methods
  • Exploiting an antibody mimetic framework
  • Binding proteins for protein microarray applications
  • Therapeutic strategies
  • 9:40 EXPLOITING TECHNOLOGY

    Dr Ton Logtenberg

    Dr Ton Logtenberg, Chief Scientific Officer, Crucell

  • MAbstract subtractive screening of diseased versus healthy tissues and cells
  • Discovery of unconventional targets using MAbstract
  • Complementing genomics and proteomics approaches
  • Strong patent position on targets and antibodies
  • 10:20 DRUG TARGET VALIDATION

    Dr Gerald Beste

    Dr Gerald Beste, Director, Combinatorial Biology, Xerion Pharmaceuticals

  • Target validation - a bottle neck in drug discovery
  • Chromophore-assisted laser inactivation (CALI) – a tool for target validation
  • Phage display as a source of binders
  • Future challenges in target validation
  • 11:00 Morning Coffee

    11:20 USING PHAGE DISPLAY TO UNDERSTAND THE HUMAN GENOME

    Dr Lutz Jermutus

    Dr Lutz Jermutus, Director, Antibody Engineering, Cambridge Antibody Technology

  • Phage display - validation of gene function via phage display (case study) - selection of neutralising antibodies against genomics-derived targets (case studies) - industrialising drug discovery using antibody phage display
  • Ribosome display - complementary alternative to phage display - specific advantages (case studies)
  • 12:00 HUMAN ANTIBODY DRUG CANDIDATES

    Dr Christian Frisch

    Dr Christian Frisch, Associate Director, Research & Development, MorphoSys

  • The next generation of HuCAL® libraries
  • HuCAL® - EST technology for high throughput target validation
  • HuCAL® as a source of drug candidates
  • Profiling of biologically active antibodies
  • 12:40 Networking Lunch

    14:00 THERAPEUTIC APPLICATIONS

    Dr Anand Gautam

    Dr Anand Gautam, Senior Vice President, Pharmexa

  • AutoVac approach targeting pathogenic self proteins in chronic diseases
  • Advantages of AutoVac: active versus passive immunotherapy
  • Bypassing immunological tolerance against pathogenic self proteins
  • Models of inflammation, bone loss, asthma and cancer and AutoVac
  • Current ongoing clinical trials using AutoVac technology
  • 14:40 INTELLECTUAL PROPERTY

    Dr Diane Wilcock

    Dr Diane Wilcock, Head, Intellectual Property, Cambridge Antibody Technology

  • Types of IP
  • Strategies for protecting technology
  • Strategies for protecting antibody products
  • Patent litigation
  • Patent licensing
  • Future perspectives
  • 15:20 Afternoon Tea

    15:40 STRATEGIC CONSIDERATIONS

    Robert Thong

    Robert Thong, Managing Director, Phizz Rx

  • Defining competitive space in the market for discovery platform technologies
  • Positioning phage display in this competitive space
  • Broadening the technology portfolio
  • Evolving into a therapeutics company
  • Leveraging mergers, acquisitions and alliance
  • 16:20 LICENSING OPPORTUNITIES

    Samta Kundu

    Samta Kundu, Associate Director, Dyax

  • Access to phage display libraries and technology - Peptides - Antibodies - Other proteins
  • Applications - Reagents - Therapeutics - Protein Purification
  • Dyax business relationship models
  • 17:00 Chairman's Closing Remarks and Close of Conference

    +

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.